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http:WHAT THIS PAPER ADDS
Few data are available concerning the feasibility, safety, and efﬁcacy of ultrasound-accelerated, catheter-
directed thrombolysis (UACDT) in “chronic” lower extremity deep vein thrombosis. Our study illustrates the
beneﬁcial role of UACDT using the EkoSonic system. Importantly, the study showed a higher treatment success
rate with signiﬁcant reduction in thrombolytic duration, thrombolytic dosage, and hemorrhagic complications.
Additional clinical studies are necessary to validate the beneﬁt and corroborate our results.Objective: To evaluate the feasibility, efﬁcacy and safety of ultrasound-accelerated catheter-directed
thrombolysis (UACDT) in the delayed treatment of lower extremity deep venous thrombosis (DVT).
Design: Twelve patients with unilateral iliofemoral or femoropopliteal DVT (mean symptom duration 92  44
days) were prospectively investigated.
Method: UACDT was performed using recombinant human tissue plasminogen activator delivered using the EKOS
EkoSonic system. Stents were deployed if indicated by post-procedure venography. Follow-up comprised weekly
duplex ultrasound for 1 month and monthly thereafter.
Results: Successful thrombolysis occurred in 11/12 limbs (92%; complete 6/12, partial 5/12) after a mean
infusion time of 26  7 hours. 2/12 patients required angioplasty and stent insertion. At a mean follow-up of 9
(6e15) months, 10/11 (91%) veins were patent whereas 1/11 re-occluded at 2 months (patient with protein-C
deﬁciency). 2/11 limbs developed symptoms/signs of post-thrombotic syndrome and 3/11 had developed deep
vein reﬂux (duplex ultrasound). 2/12 patients experienced peri-catheter bleeding but no major hemorrhage or
symptomatic pulmonary embolism occurred.
Conclusions: This preliminary evidence suggests that UACDT may be a safe and effective option for the delayed
treatment of lower limb DVT.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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UltrasoundINTRODUCTION
Deep venous thrombosis (DVT) of the lower extremity is
recognized as a cause of both pulmonary embolism (PE) and
the post-thrombotic syndrome (PTS).1 Although anti-
coagulation is currently considered the standard of care to
prevent PE and recurrent DVT, it remains ineffective in
removing thrombus burden and consequently does not
prevent PTS, which can appear months to years after an
acute DVT.2
A novel technique, ultrasound-accelerated catheter-
directed thrombolysis (UACDT), has been developed to
rapidly and completely lyse existing thrombus, therebyresponding author. M. Dumantepe, Merit Life Park Sitesi, B Blok,
Daire: 5, Serifali/Umraniye 34660, _Istanbul, Turkey.
il address: mdumantepe@gmail.com (M. Dumantepe).
-5884/$ e see front matter  2013 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2013.05.019decreasing the potential risk of PTS.3,4 The mechanism
proposed is that this technique integrates high-frequency,
low-intensity ultrasound (US) with standard catheter-
directed thrombolysis (CDT) in order to accelerate clot
dissolution, reducing treatment time, drug dosage, and the
incidence of thrombolysis-related complications. US waves
are known to increase permeability of biological structures
including tissue, vessel walls, and thrombus. This increased
permeability combined with the pressure gradient associ-
ated with an acoustic ﬁeld is thought to facilitate delivery of
therapeutic agents into, and past, older organized thrombus
into regions where dissolvable clot remains.5,6
Several studies demonstrate evidence of safety and
effectiveness in removing acute venous thrombosis using
EKOS,7e9 but limited data are available supporting its use
for chronic DVT, particularly in patients with long-standing
symptoms. Treatment of chronic DVT has long been a clin-
ical problem as the thrombus has a tendency to adhere and
organize after the acute stage. Therefore, the aim of this
M. Dumantepe et al. 367study is to examine the feasibility of using UACDT as a safe
and effective option to treat patients with chronic DVT
deﬁned as having symptoms for greater than 28 days.Figure 1. EKOS System, consisting of a multi-lumen infusion
catheter with removable coaxial ultrasound core and a control
unit, simultaneously delivers high-frequency, low-energy (2.2 MHz,
0.45 W) ultrasound energy and thrombolytic drug into the
thrombus. Ultrasound exposure enhances the permeability of the
thrombus to the lytic agent.METHODS
Study patients
Between September 2009 and October 2011, 21 consecu-
tive patients who had a ﬁrst episode of proximal DVT were
considered for this prospective study. Patients with chronic
lower extremity DVT were eligible. The diagnosis of DVT was
conﬁrmed by duplex ultrasound (DUS) and venography. For
this purpose, a Toshiba Xario SSA-660A series (Toshiba
Medical System Corporation, Nasu-Tokyo, Japan) color
Doppler ultrasound system was used with a 4.8e11 MHz
(Toshiba PLT 704 AT) linear transducer. Proposed exclusion
criteria included isolated infrapopliteal thrombosis, recur-
rent ipsilateral DVT, pre-existing leg ulcers, a short life ex-
pectancy or contraindications to anticoagulation, contrast
media, and thrombolytic agents. Contraindications to
thrombolytic agents were considered to be active internal
bleeding, recent cerebrovascular accident, allergy to
thrombolytic agents, recent major surgery, recent serious
gastrointestinal bleeding, recent serious trauma or preg-
nancy. Computerized tomography angiography (CTA) was
used to exclude subclinical pulmonary embolism, prior to
the UACDT in all patients. Informed consent for participa-
tion in the study was obtained according to the guidelines
of our institutional review board and the local ethics com-
mittee, which approved the study.Treatment procedure
The procedures were performed in a hybrid vascular oper-
ating room. Patients were positioned prone and the popli-
teal vein was catheterized with a 6 F micro access set under
DUS guidance using a 21 G needle and a 0.46 mm diameter
guide wire after which ascending venography was per-
formed. UACDT was performed using the EKOS EkoSonic
Endovascular System (EKOS Corporation, Bothell, WA, USA).
A 5.4 F multi-lumen drug delivery catheter and matching
US coaxial core wire are provided by the manufacturer with
treatment zone lengths varying between 6 and 50 cm
(Fig. 1). The drug delivery catheter was navigated over a
0.035 inch guide wire so that the treatment zone traversed
the entire clot and the tip exited the thrombus. After ﬁnal
positioning, the guide wire was exchanged for a matching
US core wire containing a series of US transducer elements
(2.2 MHz, 0.45 W) distributed approximately 1.0 cm apart
to evenly deliver US energy radially along the distal coaxial
infusion zone. After priming the drug lumens of the cath-
eter with sub-therapeutic unfractionated heparin (1,000 U/
mL), continuous infusion of the thrombolytic agent was
initiated through the side-holes along the treatment zone of
the UACDT infusion catheter. A recombinant human tissue
plasminogen activator (tPA), Alteplase (Actilyse, Boehringer
Ingelheim GmbH, Germany), was given in a 5 mg bolus
followed by an infusion at 0.02 mg/kg/hr during thetreatment. US energy was initiated via the core wire,
simultaneously with the infusion of the tPA. The system
control unit, which monitors temperature and power in the
infusion zone via a series of thermocouples in the catheter,
automatically adjusted power to optimize lysis of the
treated segment.
Patients were followed up in the intensive care unit and
continuously monitored to detect clinical signs and symp-
toms of complications such as pulmonary embolism or
hemorrhage. Blood samples were taken every 12 hours for
hematocrit, hemoglobin, partial thromboplastin time,
ﬁbrinogen, and platelet count to adjust the heparin dose
and detect potential blood loss.
We made the decision of when to stop thrombolytic
therapy based on each patient’s disease and anatomy,
graphical information displayed on the ultrasound system
control unit and control venographies taken. We stopped
UACDT when we transferred a patient to the angiography
suite. Venography was performed before removing the
introducer to determine whether there was recanalization
of the treated vein. If we did not believe that recanalization
of the target vessel was adequate at venography, we then
reinserted the drug delivery catheter back into the target
vessel and continued the UACDT for an additional 12 hours.
If the patient had chronic DVT, if the length of occlusion was
long or if the patient had a very large thrombus burden, we
performed thrombolytic treatments for as long as 39 hours.
After thrombolysis, further adjunctive procedures con-
sisting of PTA and stent placement were performed if there
was an underlying iliac vein stenosis >50%.
Warfarin sodium was routinely started prior to hospital
discharge and this was continued for at least 6 months, with
the dose adjusted to maintain an international normalized
ratio (INR) of 2.0e3.0. Adjuvant elastic compression therapy
was recommended and encouraged for more than 1 year.
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resolution
Venous recanalization after completion of treatment was
determined by comparing the thrombus scores3 of the pre-
and post-treatment venograms, which was categorized as
“complete” recanalization for 95e100% restoration of
patency, “partial” for 50e95% and “minimal” for less than
50% as a result of residual stenosis or organized
thrombus.10,11 The ﬁnal score was calculated as the per-
centage difference between pre- and post-treatment
venograms. Relief of symptoms (pain and swelling) at the
completion of treatment was rated as (i) absent, (ii) poor,
(iii) signiﬁcant, or (iv) complete. Clinical success was deﬁned
as achieving at least 50% thrombus resolution and imme-
diate clinical improvement of symptoms deﬁned as resolu-
tion of pain or swelling following thrombolysis.Table 1. Patients’ baseline characteristics.
Variable
Age (year, range) 46.1 (33e62)
Gender (female/male) 7/5
Reported symptom duration (days, range) 92.4 (34e183)
Affected limb (left/right) 8/4Follow-up
After hospital discharge, all patients were followed in the
outpatient clinic, weekly during the ﬁrst month and then at
monthly intervals. At each visit, every patient underwent a
clinical evaluation according to a modiﬁed Villalta scale12
and a DUS assessment of the affected lower limb for
patency of the deep venous system and presence or
absence of residual thrombus in the treated veins as well as
venous reﬂux. The presence of ﬁve leg symptoms (pain,
cramps, heaviness, pruritus, and paresthesia) and six
objective signs (pretibial edema, skin induration, hyperpig-
mentation, new venous ectasia, redness, and pain during
calf compression) were scored. Each of the symptoms and
signs were rated as 0 (absent), 1 (mild), 2 (moderate) or
(severe). Clinical evaluation outcomes were classiﬁed as
follows: a total score greater than 14 points or a venous
ulcer was deﬁned as severe post-thrombotic syndrome
(PTS); 5e14 points was considered to indicate mild PTS, and
less than 5 points was given for no PTS. Post-treatment DUS
assessment of the affected lower limb was also performed
at weekly intervals for 1 month, and monthly thereafter.
Valvular reﬂux was deﬁned as greater than 0.5 seconds for
the valve closure time after distal compression and release
using an ultrasonic probe with the patient standing and
non-weight bearing on the treated limb.13 Primary patency
was deﬁned as conﬁrmed patency and <50% restenosis at
the sixth month as documented by DUS.14 We recorded
limb circumferences in the thigh at 15 cm above the knee
joint and in the calf at 10 cm below the tibial tuberosity
prior to treatment and at the 6-month post-treatment
review.Thrombosis location
Iliofemoral 5
Femoropopliteal 7
Risk factors
Postpartum 3
Postoperation 1
Trauma 2
Immobilization 4
Malignancy 2Complications
Complications were classiﬁed according to scoring system of
the Society of Interventional Radiology.15 Complications not
requiring therapy and presenting without consequence or
complications requiring nominal therapy and without a
consequence, including an overnight admission for obser-
vation, were considered “minor”.RESULTS
Patients
Of the 21 patients evaluated, nine were excluded because
of previous ipsilateral DVT (n ¼ 3), pre-existing leg ulcers or
venous insufﬁciency (n ¼ 2), poor life expectancy (n ¼ 1),
recent cerebrovascular accident (n ¼ 1), or inability to
participate at follow-up visits (n ¼ 2). The remaining 12
patients were enrolled in this study. Their baseline charac-
teristics are shown in Table 1. Mean total alteplase dose
was 42.4  7.9 (range 30e54) mg and the mean infusion
time was 26.2  7.0 (range 16e39) hours. The location of
thrombosis was in the iliofemoral segment in ﬁve patients
and the femoropopliteal segment in seven patients. The
drug delivery catheter was successfully positioned within
the occlusions and UACDT was successfully performed in all
patients. There were no device failures or adverse events
associated with the EKOS system. Thrombolysis was suc-
cessful in 11 of 12 patients (92%) with complete clot lysis
(>95% restored patency) in six patients and partial clot lysis
(50e95% restored patency) in ﬁve patients. In one patient
presenting with 154 days since onset of symptoms,
thrombolysis was not successful with only minimal clot lysis
(<50%). Figs. 2 and 3 illustrate representative cases.
A statistically signiﬁcant correlation was found between the
percentage of thrombus removal and degree of clinical
improvement (p < .01, Table 2). Two patients treated for
iliofemoral DVT showed symptoms of associated iliac vein
stenosis and were further treated to improve ﬂow with
balloon angioplasty and stent implantation (60/16 mm
Wallstent, 40/10 mm Nitinol stent and 100/14 mm Wall-
stent, respectively) immediately after control venography
(Fig. 3).
Immediate clinical improvement was observed in 11 of
12 patients, with signiﬁcant or complete clinical improve-
ment occurring in 10. These patients also exhibited over
50% of thrombus clearance. All together, clinical success
was observed in 10 patients (83%). In the follow-up period,
thigh circumference of the affected limb decreased by
3.9  1.7 cm, and calf circumference decreased by
3.3  1.5 cm in the ﬁrst month (Table 3).
Figure 2. (A) Images from a 34-year-old woman who presented with non-acute left lower extremity DVT. The duration of thrombotic
occlusions was 34 days. (B) EKOS catheter with a 50 cm treatment length was placed into the thrombus. (C) Follow-up venogram shows
complete resolution of thrombus after 24 hours infusion. (D) No underlying stenosis.
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Bleeding at the catheter insertion site occurred in two pa-
tients (17%). The bleeding was controlled in both cases by
simple elevation of the limb and application of a
compressive bandage, without requiring transfusion or
interruption of the procedure. A further patient experi-
enced hematuria after 34 hours on alteplase, with sponta-
neous remission after interruption of lytic infusion. No
patient suffered from serious complications.Follow-up
The follow-up duration for the 11 patients successfully
treated with UACDT was 6e15 (mean 9) months with 10
limbs (91%) still patent at 270 days post procedure, as
determined by DUS. One patient with protein-C deﬁciency,
who achieved complete lysis, experienced reocclusion 2
months after treatment. Primary patency was observed in
the remaining 10 patients. Two of the 12 limbs (18%)
developed mild PTS that mainly presented as pain, heavi-
ness, and edema of the affected limbs after activities. Mild
pruritus was also present in three limbs, but none of theseFigure 3. Venograms exhibiting complete thrombolysis of left femoro-
common iliac vein, treated with angioplasty and stent placement. The d
in prone position; ascending venogram demonstrated heavy thrombus b
of UACDT, ﬂow was restored within the femoro-popliteal vein. (C) How
observed. (D) Iliac stenosis was treated with angioplasty and stent plac
the left common iliac vein.had severe PTS. The median total PTS score was 4 (range 0e
9), and seven limbs (64%) had a score <3. Valvular reﬂux
occurred in three (27%) limbs and valvular function was
normal in eight patients, as observed with DUS.DISCUSSION
The goal in treating chronic DVT is to restore ﬂow by
adequately recanalizing the obstructed venous segment and
to maintain its patency, thus minimizing the risk and
severity for PTS. The current study demonstrates the
promise for UACDT to achieve early and late success with
evidence of effective recanalization and rapid resolution of
pain and swelling and persisting patency and absence of
reﬂux at follow-up in this small group of patients with
chronic thrombosis. There was also a low rate of bleeding
complications. The results contrast with those associated
with conventional therapy of anticoagulation with heparin
then warfarin, where recanalization depends solely on
the endogenous ﬁbrinolytic system. PTS has been reported
to develop in 20e50% of these patients within 1e2 years,
of which 5e10% develop severe PTS.16,17 Results alsopopliteal vein, as well as the underlying focal stenosis of the left
uration of thrombotic occlusions was 76 days. (A) With the patient
urden extending into the common femoral vein. (B) After 23 hours
ever, a focal stenosis (arrow) within the left common iliac vein was
ement. (E) Final venogram showing complete restoration of ﬂow in
Table 2. Clinical improvement and initial results of thrombolysis.
Limb Onset of
symptoms (days)
% of
thrombolysis
Clinical
improvement
Infusion
time/h
Alteplase
dose (mg)
Venous stenosis
or occlusion
Complications
1 L 59 95 þþþ 21 38
2 L 34 100 þþþ 16 30
3 R 87 76 þþ 22 46 Hematoma
4 L 125 74 þþ 27 43
5 R 47 100 þþþ 18 36
6 L 154 28 e 30 50
7 L 76 95 þþþ 23 31 CIV
8 L 183 75 þþ 34 54 Hematuria
9 R 58 100 þþþ 22 37
10 L 96 60 þ 33 51
11 R 77 95 þþþ 39 45 CIV Hematoma
12 L 113 70 þþ 30 48
L ¼ left; R ¼ right; () ¼ absent; (þ) ¼ poor; (þþ) ¼ signiﬁcant; (þþþ) ¼ complete; CIV ¼ common iliac vein.
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rate of 30% has been calculated from pooled data.18
Mewissen et al.3 reported that treatment with catheter-
directed urokinase for a mean of 53 hours in 473 DVT pa-
tients resulted in complete thrombus clearance in only 31%
of the patients, with bleeding complications seen in 27%
including 11% with major bleeding.
These results appear to justify UACDT use with the Eko-
Sonic endovascular system, which combines high-frequency,
low-power US with simultaneous catheter-directed throm-
bolytics to accelerate clot dissolution. It is postulated that it
acts by ﬁrst disassociating the ﬁbrin mesh to increase
permeability of the thrombus, making plasminogen re-
ceptors available to the thrombolytic agent. At the same
time, acoustic microstreaming caused by the US wave
pressure is believed to drive the thrombolytic agent away
from the catheter deep into the loosened thrombus.19
Motarjeme20 and Parikh et al.21 were the ﬁrst to report
use of UACDT in DVT. They reported signiﬁcantly higher
complete clot lysis rates with UACDT compared with stan-
dard CDT, without raising bleeding or thromboembolic risk.
UACDT is reported to be effective also for treating periph-
eral arterial occlusions, massive PE,22 and acute ischemic
stroke.23
The primary limitation of the current study is the small
patient population of only 12 patients. Clearly, additional
clinical studies will be necessary to further validate the
beneﬁts and corroborate our results. Although the mean
clinical follow-up time at 9 months may be insufﬁcient to
observe late changes related to PTS such as cutaneousTable 3. Change of affected limb circumference pre- and post-
treatment (n ¼ 11).
Measurement
locationa
Affected limb
circumference
(mean  SD, cm)
Difference
(mean  SD, cm)
Pre-
treatment
Post-
treatment
Thigh 36.4  1.6 32.5  1.5 3.9  1.7
Calf 30.4  1.3 27.1  1.8 3.3  1.5
a Thigh circumference was assessed at 15 cm above knee joint and
calf circumference was assessed at 10 cm below tibial tuberosity.hyperpigmentation and phlebopathic ulcers, we believe it is
adequate to assess early signs of venous insufﬁciency. We
recognize that deﬁning chronicity of thrombus based solely
on the age of symptoms may not be adequate when making
clinical decisions. We believe that the location of thrombus,
its consistency, medical therapy initiation time, use of
compression stockings, dose of anticoagulation medication,
and other factors may also play a role in successful clinical
outcomes. A more reliable classiﬁcation of clot age is
necessary but is beyond the scope of this study.
In summary, our study suggests that UACDT using the
EkoSonic system can produce a higher treatment success
rate with signiﬁcant reduction in thrombolytic duration,
thrombolytic dosage, and hemorrhagic complications when
treating chronic lower extremity DVT than other forms of
treatment.
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